Glycerol-3-phosphate dehydrogenase 1 deficiency is a rare autosomal recessive disorder caused by mutations in the gene (GPD1; OMIM*138420). Very few cases are reported in literature. It usually manifests in early infancy with transient hypertriglyceridemia, hepatomegaly, steatosis, and fibrosis. We report the case of a 16-year-old boy followed since the age of 1 year for hepatomegaly, elevated liver enzymes, and persistent hypertriglyceridemia. Abdominal ultrasound showed diffuse liver echogenicity and liver biopsy disclosed cirrhosis with micro and macrovesicular steatosis. Next-generation sequencing for metabolic and genetic liver diseases was conducted with the identification of the homozygous mutation c.895G>A in gene resulting in the aminocidic substitution p.G299R. Considering the persistent and progressive increase of plasma triglycerides, fenofibrate treatment was started at 15 years of age allowing triglyceride level reduction in the following 1-year follow-up.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7358666PMC
http://dx.doi.org/10.1002/jmd2.12125DOI Listing

Publication Analysis

Top Keywords

persistent hypertriglyceridemia
8
glycerol-3-phosphate dehydrogenase
8
dehydrogenase deficiency
8
successful fenofibrate
4
fenofibrate therapy
4
therapy severe
4
severe persistent
4
hypertriglyceridemia boy
4
boy cirrhosis
4
cirrhosis glycerol-3-phosphate
4

Similar Publications

Acquired generalized lipodystrophy (AGL) is a rare complication of immune checkpoint inhibitors (ICIs) and is associated with immune-mediated loss of adipose tissue, peripheral resistance to insulin, and serious metabolic complications. Here we report a new case of ICI-induced AGL and provide an updated literature review of published cases. We report a 39-year-old female patient treated with adjuvant pembrolizumab for stage IIIC nevoid melanoma with ICI-induced AGL.

View Article and Find Full Text PDF

Novel agents for treating severe hypertriglyceridemia.

Med

December 2024

Department of Metabolic Medicine/Chemical Pathology, Guy's & St Thomas' Hospitals, London, UK. Electronic address:

The PALISADE trial extended the data available for inhibition of apolipoprotein (apo) C3 inhibition for treating severe hypertriglyceridemia. 75 patients with persistent chylomicronemia were allocated to 2 doses of plozasiran or placebo. Triglycerides were reduced by a net 53%-58%, and a borderline significant 17% reduction was seen in pancreatitis events.

View Article and Find Full Text PDF

Familial chylomicronemia: New perspectives.

Clin Investig Arterioscler

December 2024

Unidad de Lípidos y Riesgo Cardiovascular, Servicio de Medicina Interna, Complejo Hospitalario Universitario de A Coruña, A Coruña, España. Electronic address:

Familial chylomicronemia syndrome (FCS) is a very rare, underdiagnosed disorder that can cause abdominal pain and recurrent pancreatitis from childhood -potentially life-threatening- and chronic complications such as diabetes mellitus and exocrine pancreatic insufficiency. FCS affects the quality of life and mental health of those who suffer from it, aspects that must be taken into account in its treatment, based on a strict low-fat diet, which is difficult to adhere to and persist. People with FCS lack the lipolytic capacity to hydrolyze triglycerides (TG) and have a minimal or null response to conventional lipid-lowering treatments.

View Article and Find Full Text PDF

Background & Aims: Patients with chronic kidney disease (CKD) often have additional health problems, including sarcopenia and sarcopenic obesity. These conditions involve ectopic fat accumulation within muscles. This ectopic fat deposition reduces muscle quality, leading to weaker muscle strength and poorer physical performance.

View Article and Find Full Text PDF

Dietary quality, perceived health, and psychological status as key risk factors for newly developed metabolic dysfunction-associated steatotic liver disease in a longitudinal study.

Nutrition

February 2025

Korea Department of Bioconvergence, Hoseo University, Asan, South Korea; Department of Food and Nutrition, Obesity/Diabetes Research Center, Hoseo University, Asan, South Korea. Electronic address:

Objectives: This study investigated biomarkers in individuals with newly developed metabolic dysfunction-associated steatotic liver disease (ND-MASLD) and examined the interplay between genetic predisposition and environmental factors using a machine learning approach in a large longitudinal study.

Methods: Participants were classified into four groups based on metabolic dysfunction-associated steatotic liver disease (MASLD) status between the first and second measurements with an approximate 5-y gap. A model was developed to identify early-stage biomarkers of ND-MASLD (n = 1603).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!